Ellen Strahlman Buys 3,601 Shares of Hyperion DeFi (NASDAQ:HYPD) Stock

by · The Cerbat Gem

Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) Director Ellen Strahlman purchased 3,601 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average cost of $3.86 per share, for a total transaction of $13,899.86. Following the completion of the purchase, the director owned 79,049 shares in the company, valued at $305,129.14. This trade represents a 4.77% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Hyperion DeFi Stock Down 3.7%

Hyperion DeFi stock traded down $0.13 during mid-day trading on Tuesday, reaching $3.37. The stock had a trading volume of 193,370 shares, compared to its average volume of 1,525,525. The stock’s 50-day simple moving average is $4.87 and its 200-day simple moving average is $7.60. Hyperion DeFi, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $17.99. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The firm has a market capitalization of $27.53 million, a PE ratio of -0.83 and a beta of 2.81.

Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. The business had revenue of $0.36 million during the quarter. On average, sell-side analysts forecast that Hyperion DeFi, Inc. will post -41.6 EPS for the current fiscal year.

Analyst Ratings Changes

HYPD has been the topic of several analyst reports. Wall Street Zen raised Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Cantor Fitzgerald assumed coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price target for the company. Finally, Chardan Capital set a $7.75 price objective on shares of Hyperion DeFi and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.58.

Read Our Latest Stock Report on HYPD

Hyperion DeFi Company Profile

(Get Free Report)

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.

See Also